Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A. Scholz CW, et al. Among authors: lastoria s. J Clin Oncol. 2013 Jan 20;31(3):308-13. doi: 10.1200/JCO.2011.41.1553. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233718 Clinical Trial.
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
Corazzelli G, Frigeri F, Arcamone M, Aloj L, Capobianco G, Becchimanzi C, Morelli E, Volzone F, Marcacci G, Russo F, De Filippi R, Lastoria S, Pinto A. Corazzelli G, et al. Among authors: lastoria s. Eur J Haematol. 2011 Dec;87(6):547-53. doi: 10.1111/j.1600-0609.2011.01683.x. Epub 2011 Jul 31. Eur J Haematol. 2011. PMID: 21752099 Free PMC article.
Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
Arrichiello C, Aloj L, Mormile M, D'Ambrosio L, Frigeri F, Caracò C, Arcamone M, De Martinis F, Pinto A, Lastoria S. Arrichiello C, et al. Among authors: lastoria s. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):956-66. doi: 10.1007/s00259-011-2040-5. Epub 2012 Jan 12. Eur J Nucl Med Mol Imaging. 2012. PMID: 22237846 Clinical Trial.
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.
Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco' C, Di Gennaro F, Capobianco G, Giovannoni L, Menssen HD, Neri D, Pinto A, Lastoria S. Aloj L, et al. Among authors: lastoria s. Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24435772 Clinical Trial.
A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A. Russo F, et al. Among authors: lastoria s. Br J Haematol. 2014 Jul;166(1):118-29. doi: 10.1111/bjh.12862. Epub 2014 Mar 27. Br J Haematol. 2014. PMID: 24673727 Free article. Clinical Trial.
The role of radiolabeled somatostatin analogs in adrenal imaging.
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M. Maurea S, et al. Among authors: lastoria s. Nucl Med Biol. 1996 Aug;23(6):677-80. doi: 10.1016/0969-8051(96)00065-0. Nucl Med Biol. 1996. PMID: 8940709 Clinical Trial.
178 results